当前位置:首页 - 行情中心 - 恒瑞医药(600276) - 财务分析 - 现金流量表

恒瑞医药

(600276)

  

流通市值:3255.84亿  总市值:3255.84亿
流通股本:63.79亿   总股本:63.79亿

现金流量表

报告期2024-12-312024-09-302024-06-302024-03-31
公司类型通用通用通用通用
一、经营活动产生的现金流量:
销售商品、提供劳务收到的现金27,146,811,001.2520,000,144,131.4613,505,722,033.494,998,626,088.98
收到的税费返还---5,233,902.35
收到其他与经营活动有关的现金1,322,070,742.88546,652,931.24332,597,535.781,132,191,375.65
经营活动现金流入的平衡项目0000
经营活动现金流入小计28,468,881,744.1320,546,797,062.713,838,319,569.276,136,051,366.98
购买商品、接受劳务支付的现金1,402,150,450.751,130,472,262.16784,683,468.64318,169,725.31
支付给职工以及为职工支付的现金6,163,445,682.384,610,758,220.713,100,793,377.511,532,162,227.17
支付的各项税费2,290,150,446.161,652,291,637.651,256,569,717.17467,797,855.85
支付其他与经营活动有关的现金11,190,382,126.138,567,828,933.065,663,518,164.772,563,322,649.65
经营活动现金流出的平衡项目0000
经营活动现金流出小计21,046,128,705.4215,961,351,053.5810,805,564,728.094,881,452,457.98
经营活动产生的现金流量净额平衡项目0000
经营活动产生的现金流量净额7,422,753,038.714,585,446,009.123,032,754,841.181,254,598,909
二、投资活动产生的现金流量:
收回投资收到的现金605,485,304.68200,000,000--
取得投资收益收到的现金52,505,139.4543,037,372.9535,223,637.559,009,741.47
处置固定资产、无形资产和其他长期资产收回的现金净额21,901,7398,183,649.55,857,667.511,621,876.59
投资活动现金流入的平衡项目0000
投资活动现金流入小计679,892,183.13251,221,022.4541,081,305.0610,631,618.06
购建固定资产、无形资产和其他长期资产支付的现金1,969,197,487.861,524,667,512.24964,673,726.04561,021,859.6
投资支付的现金622,680,411.5600,000,000600,000,000200,000,000
投资活动现金流出的平衡项目0000
投资活动现金流出小计2,591,877,899.362,124,667,512.241,564,673,726.04761,021,859.6
投资活动产生的现金流量净额平衡项目0000
投资活动产生的现金流量净额-1,911,985,716.23-1,873,446,489.79-1,523,592,420.98-750,390,241.54
三、筹资活动产生的现金流量:
取得借款收到的现金799,909,380.08799,909,380.08799,909,380.08-
筹资活动现金流入平衡项目000-
筹资活动现金流入小计799,909,380.08799,909,380.08799,909,380.08-
偿还债务支付的现金799,909,380.08799,909,380.08799,909,380.08-
分配股利、利润或偿付利息支付的现金1,274,788,274.051,274,788,274.051,019,953.25-
支付其他与筹资活动有关的现金275,801,751.83231,735,776.01137,547,567.6318,134,576.37
筹资活动现金流出平衡项目0000
筹资活动现金流出小计2,350,499,405.962,306,433,430.14938,476,900.9618,134,576.37
筹资活动产生的现金流量净额平衡项目0000
筹资活动产生的现金流量净额-1,550,590,025.88-1,506,524,050.06-138,567,520.88-18,134,576.37
四、汇率变动对现金及现金等价物的影响7,400,551.34-21,219,513.59-5,838,450.66-18,208,185.01
现金及现金等价物净增加额平衡项目0000
五、现金及现金等价物净增加额3,967,577,847.941,184,255,955.681,364,756,448.66467,865,906.08
加:期初现金及现金等价物余额20,271,524,269.7220,271,524,269.7220,271,524,269.7220,271,524,269.72
期末现金及现金等价物余额平衡项目0000
期末现金及现金等价物余额24,239,102,117.6621,455,780,225.421,636,280,718.3820,739,390,175.8
补充资料:
净利润6,336,994,647.53-3,428,132,358.04-
资产减值准备32,538,341.38--15,816,450.54-
固定资产和投资性房地产折旧655,021,624.88-313,708,012.88-
其中:固定资产折旧、油气资产折耗、生产性生物资产折旧655,021,624.88-313,708,012.88-
无形资产摊销67,263,980.25-28,223,961.4-
长期待摊费用摊销94,789,854.75-49,076,304.56-
处置固定资产、无形资产和其他长期资产的损失-5,397,912.01--2,015,408.01-
固定资产报废损失4,944,029.96-1,868,321.58-
公允价值变动损失-108,630,771.57--7,542,196.34-
财务费用-1,841,800.26--11,929,279.97-
投资损失-23,868,290.32-6,007,841.47-
递延所得税-23,141,400.15--82,332,187.42-
其中:递延所得税资产减少-56,618,467.73--83,786,038.15-
递延所得税负债增加33,477,067.58-1,453,850.73-
存货的减少-135,630,816.98-77,839,354.29-
经营性应收项目的减少-375,699,363.85--2,548,575,946.35-
经营性应付项目的增加671,408,644.5-1,614,929,285.73-
其他209,255,274.64-109,865,787.99-
现金的期末余额24,239,102,117.66-21,636,280,718.38-
减:现金的期初余额20,271,524,269.72-20,271,524,269.72-
公告日期2025-03-312024-10-252024-08-222024-04-18
审计意见(境内)标准无保留意见
TOP↑